GW Pharmaceuticals, a world leader in discovering, developing and commercializing cannabinoid prescription medicines, announced that the European Commission (EC) has approved the marketing authorisation for EPIDYOLEX® for use as adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet […]
The Dank Investor is an industry leading cannabis financial services company providing breaking market news, analysis and leading insights about cannabis stocks for investors to grow their portfolios and minimize risk. Markets include NASDAQ, NYSE, OTC and other markets. Additionally, the company provides business services to companies in the cannabis sector through comprehensive corporate communication and marketing solutions.
The Dank Investment Community encompasses an engaged social media audience of over 50,000 who leverage our content to stay informed as investors.
We seek Safe Harbor.
